What is the current stock price of Greenwich LifeSciences, Inc. (GLSI)?

As of the latest market data, Greenwich LifeSciences, Inc. (GLSI) is trading at $27.65. The stock has seen a gain of 1.69% today.

Does Greenwich LifeSciences, Inc. (GLSI) pay a dividend?

Based on current data, Greenwich LifeSciences, Inc. does not have a confirmed active dividend policy.

What is the market cap of Greenwich LifeSciences, Inc.?

The current market capitalization of Greenwich LifeSciences, Inc. (GLSI) is approximately unavailable.

GLSI

Greenwich LifeSciences, Inc.·Healthcare

27.65

1.692%(+0.46)

Market Closed

29.10

5.244%(+1.45)

After Hours

Last Updated: — ET

52W L: $7.7852W H: $34.10

GLSI NEWS

globenewswire.com

20h ago

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

STAFFORD, Texas, May 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) ("Greenwich" or the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that on May 20, 2026, the Company received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, because it has not yet filed its Quarterly Report on Form 10-Q for the three months ended March 31, 2026, the Company is not currently in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission.

globenewswire.com

20h ago

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

globenewswire.com

Apr 30

Greenwich LifeSciences Provides Update Regarding Form 10-K Filing

STAFFORD, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on its Form 10-K filing for the fiscal year ending December 31, 2025.

globenewswire.com

Apr 30

Greenwich LifeSciences Provides Update Regarding Form 10-K Filing

globenewswire.com

Apr 23

Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026

STAFFORD, Texas, April 23, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that an abstract has been accepted for publication at the upcoming 2026 ASCO Annual Meeting along with a corresponding poster presentation.

globenewswire.com

Apr 23

Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026

Company Profile

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2020-09-25

Beta

1.39

Websitegreenwichlifesciences.com↗